# language_name_wals:	English
# language_name_glotto:	English
# ISO_6393:	eng
# year_composed:	NA
# year_published:	NA
# mode:	written
# genre_broad:	technical
# genre_narrow:	NA
# writing_system:	Latn
# special_characters:	NA
# short_description:	EMEA
# source:	https://object.pouta.csc.fi/OPUS-EMEA/v3/raw/en.zip
# copyright_short:	http://opus.nlpl.eu/EMEA.php
# copyright_long:	http://opus.nlpl.eu/EMEA.php J. Tiedemann, 2012, Parallel Data, Tools and Interfaces in OPUS. In Proceedings of the 8th International Conference on Language Resources and Evaluation (LREC 2012)
# sample_type:	whole
# comments:	NA

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
1 1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Ingelvac CircoFLEX suspension for injection for pigs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 1 ml of inactivated vaccine contains:
Active substance:
Porcine circovirus type 2 ORF2 protein: minimum RP* 1.0 maximum RP* 3.75 * Relative Potency (ELISA test) by comparison with a reference vaccine
Adjuvant:
Carbomer
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for injection.
4.
CLINICAL PARTICULARS
4.1 Target species
Pigs (from 2 weeks of age)
4.2 Indications for use, specifying the target species
For active immunisation of pigs over the age of 2 weeks against Porcine Circovirus Type 2 (PCV2) to reduce mortality, clinical signs - including weight loss - and lesions in lymphoid tissues associated with PCV2 related disease (PCVD).
In addition, vaccination has been shown to reduce PCV2 nasal shedding, viral load in blood and lymphoid tissues, and duration of viraemia.
Onset of protection occurs as early as 2 weeks post vaccination and lasts for at least 17 weeks.
4.3 Contraindications
None.
4.4 Special warnings
None.
4.5 Special precautions for use
Special precautions for use in animals
Avoid introduction of contamination during use.
Only healthy animals should be vaccinated.
2 Special precautions to be taken by the person administering the veterinary medicinal product to animals
None.
4.6 Adverse reactions (frequency and seriousness)
A mild and transient hyperthermia very commonly occurs on the day of vaccination.
4.7 Use during pregnancy, lactation or lay
Do not use during pregnancy and lactation.
4.8 Interaction with other medicinal products and other forms of interaction
No information is available on the compatibility of this vaccine with any other.
Therefore the safety and efficacy of this product when used with any other (either when used on the same day or at different times) has not been demonstrated.
4.9 Amounts to be administered and administration route
Shake well before use.
Single intramuscular injection of one dose (1 ml), irrespective of body weight.
Use vaccination devices according to the manufacturer's instruction.
Avoid multiple broaching.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
Following the administration of a 4-fold overdose of vaccine no adverse reactions other than those described under section 4.6. have been observed.
4.11 Withdrawal period
Zero days.
5.
IMMUNOLOGICAL PROPERTIES
Pharmacotherapeutic group:
Inactivated Porcine circovirus vaccine
ATC vet code:
QI09AA07
This vaccine is designed to stimulate the development of an active immune response to Porcine circovirus type 2.
6.
PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Sodium chloride Water for injection
3 6.2 Incompatibilities
Do not mix with any other vaccine or immunological product.
6.3 Shelf life
Shelf life of the veterinary medicinal product as packaged for sale:
15 months.
Use immediately after opening.
6.4 Special precautions for storage
Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Protect from light.
6.5 Nature and composition of immediate packaging
High density polyethylene bottles of 10 ml, 50 ml, 100 ml or 250 ml with a chlorobutyl stopper and lacquered aluminium seal.
Each bottle is packed individually in a cardboard box.
Not all pack sizes may be marketed.
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
7.
MARKETING AUTHORISATION HOLDER
Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/ Rhein Germany
8.
MARKETING AUTHORISATION NUMBER(S)
EU/ 2/ 07/ 079/ 001 10 ml EU/ 2/ 07/ 079/ 002 50 ml EU/ 2/ 07/ 079/ 003 100 ml EU/ 2/ 07/ 079/ 004 250 ml
9.
DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION
13.02.2008
4 10.
DATE OF REVISION OF THE TEXT
13.02.2008
PROHIBITION OF SALE, SUPPLY AND/ OR USE
The import, sale supply and/ or use of Ingelvac CircoFLEX is or may be prohibited in certain Member States on the whole or part of their territory pursuant to national animal health policy.
Any person intending to import, sell, supply and/ or use Ingelvac CircoFLEX must consult the relevant Member State's competent authority on the current vaccination policies prior to the import, sale, supply and/ or use.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
5 ANNEX II
A.
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
B.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE
C.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO SAFE AND EFFECTIVE USE
D.
STATEMENT OF THE MRLs
6 A.
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
Name and address of the manufacturer(s) of the biological active substance(s) Boehringer Ingelheim Vetmedica Inc.
2621 North Belt Highway, St.
Joseph, Missouri, 64506 U. S. A.
Name and address of the manufacturer(s) responsible for batch release Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/ Rhein GERMANY
B.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE
To be supplied only on veterinary prescription.
The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
According to Article 71 of Directive 2001/ 82/ EC of the European Parliament and of the Council as amended, Member States prohibit or may prohibit the import, sale, supply and/ or use of the veterinary medicinal product on the whole or part of their territory if it is established that:
a) the administration of the veterinary medicinal product to animals will interfere with the implementation of national programmes for the diagnosis, control and eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
b) the disease to which the veterinary medicinal product is intended to confer immunity is largely absent from the territory.
C.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE PRODUCT
Not applicable.
D.
STATEMENT OF THE MRLs
Sodium chloride is included in Annex II of Council Regulation (EEC) No 2377/ 90 in accordance with the following table:
Pharmacologically active substance(s)
Animal species
Other provisions
Sodium chloride
All food-producing species
Carbomer is considered not within the scope of Council Regulation (EEC) No.
2377/ 90.
7 ANNEX III
LABELLING AND PACKAGE LEAFLET
8 A.
LABELLING
9 PARTICULARS TO APPEAR ON THE OUTER PACKAGE
{10 ml; 50 ml, 100 ml, 250 ml cardboard box}
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Ingelvac CircoFLEX suspension for injection for pigs
2.
STATEMENT OF ACTIVE AND OTHER SUBSTANCES
Each dose of inactivated vaccine contains:
Porcine circovirus type 2 ORF2 protein Carbomer
3.
PHARMACEUTICAL FORM
Suspension for injection
4.
PACKAGE SIZE
10 ml (10 doses) 50 ml (50 doses) 100 ml (100 doses) 250 ml (250 doses)
5.
TARGET SPECIES
Pigs (from 2 weeks of age)
6.
INDICATION(S)
For active immunisation of pigs over the age of 2 weeks against Porcine Circovirus Type 2 (PCV2).
7.
METHOD AND ROUTE(S) OF ADMINISTRATION
Shake well before use.
Single intramuscular injection of one dose (1 ml) Read the package leaflet before use.
8.
WITHDRAWAL PERIOD
Withdrawal period:
Zero days.
10 9.
SPECIAL WARNINGS, IF NECESSARY
Read the package leaflet before use.
10.
EXPIRY DATE
EXP {month/ year} Use immediately after opening.
11.
SPECIAL STORAGE CONDITIONS
Store and transport refrigerated (2 °C - 8 °C).
Do not freeze.
Protect from light.
12.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY
Read the package leaflet before use.
13.
THE WORDS “ FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable
For animal treatment only - to be supplied only on veterinary prescription.
14.
THE WORDS “ KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”
Keep out of the reach and sight of children.
15.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Boehringer Ingelheim Vetmedica GmbH D-55216 Ingelheim/ Rhein
16.
MARKETING AUTHORISATION NUMBER(S)
EU/ 2/ 07/ 079/ 001 10 ml EU/ 2/ 07/ 079/ 002 50 ml EU/ 2/ 07/ 079/ 003 100 ml EU/ 2/ 07/ 079/ 004 250 ml
17.
MANUFACTURER’ S BATCH NUMBER
Lot {number}
11 PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE
{100 ml, 250 ml bottle}
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Ingelvac CircoFLEX suspension for injection for pigs
2.
STATEMENT OF ACTIVE AND OTHER SUBSTANCES
Each dose of inactivated vaccine contains:
Porcine circovirus type 2 ORF2 protein Carbomer
3.
PHARMACEUTICAL FORM
Suspension for injection
4.
PACKAGE SIZE
100 ml (100 doses) 250 ml (250 doses)
5.
TARGET SPECIES
Pigs (from 2 weeks of age)
6.
INDICATION(S)
For active immunisation of pigs over the age of 2 weeks against Porcine Circovirus Type 2 (PCV2).
7.
METHOD AND ROUTE(S) OF ADMINISTRATION
Single intramuscular injection of one dose (1 ml).
Read the package leaflet before use.
8.
WITHDRAWAL PERIOD
Withdrawal period:
Zero days.
9.
SPECIAL WARNINGS, IF NECESSARY
Read the package leaflet before use.
12 10.
EXPIRY DATE
EXP {month/ year} Use immediately after opening.
11.
SPECIAL STORAGE CONDITIONS
Store and transport refrigerated (2 °C - 8 °C).
Read the package leaflet before use.
12.
THE WORDS “ FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable
For animal treatment only.
13.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Boehringer Ingelheim Vetmedica GmbH Germany
14.
MANUFACTURER’ S BATCH NUMBER
Lot {number}
13 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
{10 ml, 50 ml bottle}
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Ingelvac CircoFLEX suspension for injection for pigs
2.
QUANTITY OF THE ACTIVE SUBSTANCE(S)
Each dose of inactivated vaccine contains:
Porcine circovirus type 2 ORF2 protein Carbomer
3.
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES
10 ml (10 doses) 50 ml (50 doses)
4.
ROUTE(S) OF ADMINISTRATION
IM
5.
WITHDRAWAL PERIOD
Withdrawal period:
Zero days.
6.
BATCH NUMBER
Lot {number}
7.
EXPIRY DATE
EXP {month/ year} Use immediately after opening.
8.
THE WORDS “ FOR ANIMAL TREATMENT ONLY”
For animal treatment only.
14 B.
PACKAGE LEAFLET
15 PACKAGE LEAFLET FOR:
Ingelvac CircoFLEX suspension for injection for pigs
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/ Rhein Germany
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Ingelvac CircoFLEX suspension for injection for pigs
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS
Each dose of 1 ml of inactivated vaccine contains:
Porcine circovirus type 2 ORF2 protein: minimum RP* 1.0, maximum RP* 3.75 * Relative Potency (ELISA test) by comparison with a reference vaccine.
Adjuvant:
Carbomer
4.
INDICATION(S)
For active immunisation of pigs over the age of 2 weeks against Porcine Circovirus Type 2 (PCV2) to reduce mortality, clinical signs - including weight loss - and lesions of in lymphoid tissues associated with PCV2 related diseases (PCVD).
In addition, vaccination has been shown to reduce PCV2 nasal shedding, viral load in blood and lymphoid tissues, and duration of viraemia.
Onset of immunity:
Duration of immunity:
as early as 2 weeks post vaccination at least 17 weeks.
5.
CONTRAINDICATIONS
None.
6.
ADVERSE REACTIONS
A mild and transient hyperthermia very commonly occurs on the day of vaccination.
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.
7.
TARGET SPECIES
Pigs (from 2 weeks of age)
16 8.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
Single intramuscular(IM) injection of one dose (1 ml) to pigs, irrespective of body weight.
9.
ADVICE ON CORRECT ADMINISTRATION
Shake well before use.
Use vaccination devices according to the manufacturer's instructions.
Avoid multiple vial broaching.
10.
WITHDRAWAL PERIOD
Zero days.
11.
SPECIAL STORAGE PRECAUTIONS
Keep out of the reach and sight of children.
Store and transport refrigerated (2 °C - 8 °C).
Do not freeze.
Protect from light.
Do not use after the expiry date (EXP) which is stated on the carton and the bottle.
Use immediately after opening.
12.
SPECIAL WARNING(S)
Precautions for use in animals Avoid introduction of contamination during use.
Only healthy animals should be vaccinated.
Use during pregnancy and lactation Do not use during pregnancy and lactation.
Incompatibilities No safety or efficacy information is available on the compatibility of this vaccine with any other vaccine.
It is therefore recommended that no other vaccines should be administered on the same day or at different times.
Do not mix with any other vaccine or immunological product.
13.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
Waste materials should be disposed of in accordance with local requirements.
14.
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED
13.02.2008
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
17 15.
OTHER INFORMATION
This vaccine is designed to stimulate the development of an active immune response to Porcine circovirus type 2.
Bottle of 10 ml (10 doses), 50 ml (50 doses), 100 ml (100 doses), or 250 ml (250 doses) packed individually in a cardboard box.
Not all pack sizes may be marketed.
18